



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

Food and Drug Administration  
Silver Spring, MD 20993

ANDA 91464

Teva Pharmaceuticals USA  
Attention: Jean W. Zwicker  
Senior Director, Regulatory Affairs  
425 Privet Road  
Horsham, PA 19044

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) received on April 8, 2009, and submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Solifenacin Succinate Tablets, 5 mg and 10 mg.

Reference is made to the Tentative Approval letter issued by this office on October 31, 2011, and to your amendments dated October 11, and October 22, 2012; April 19, 2013 and March 25, 2014.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Solifenacin Succinate Tablets, 5 mg and 10 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), VESicare Tablets, 5 mg and 10 mg, respectively, of Astellas Pharma US, Inc. (Astellas). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

The RLD upon which you have based your ANDA, VESicare Tablets of Astellas, is subject to a period of patent protection. As noted in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), U.S. Patent No. 6,017,927 (the '927 patent), is scheduled to expire on November 19, 2018.

Your ANDA contains a paragraph IV certification under section 505(j)(2)(A)(vii)(IV) of the Act stating that the '927 patent is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Solifenacin Succinate Tablets, 5 mg and 10 mg, under this ANDA. You have notified the agency that Teva Pharmaceuticals USA (Teva) complied with the requirements of section 505(j)(2)(B) of the Act, and that litigation was initiated against Teva for infringement of the '927 within the statutory 45-day period in the United States District Court for the Southern District of New York [Astellas Pharma, Inc. and Astellas Pharma US, Inc. v. Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., Civil Action No. 09-CIV-8100]. You have also notified the agency that the litigation has been dismissed; therefore, under section 505(j)(5)(B)(iii) your ANDA is eligible for approval.

With respect to 180-day generic drug exclusivity, we note that Teva was the first ANDA applicant for Solifenacin Succinate Tablets, 5 mg and 10 mg, to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Teva may be eligible for 180 days of generic drug exclusivity for Solifenacin Succinate Tablets, 5 mg and 10 mg. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the Act, would begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv).

(b) (4)

(b) (4)

The agency is not, however, making a formal determination at this time of Teva's eligibility for 180-day generic drug exclusivity. It will do so only if a subsequent paragraph IV applicant becomes eligible for full approval (a) within 180 days after Teva begins commercial marketing of Solifenacin Succinate Tablets, 5 mg and 10 mg, or (b) at any time prior to the expiration of the last listed patent if Teva has not begun commercial marketing. Please submit correspondence to this ANDA informing the agency of the date commercial marketing begins.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA)(Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration

and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

Kathleen Uhl, M.D.  
Acting Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research